Feed DRUG
DR

Bright Minds Biosciences Inc.

DRUG · NASDAQ

$63.18 -4.63% (-$3.07)
1M -17.35%
Market Cap $880.1M
P/E Ratio -
Div. Yield -
ROE 12.56%

Bulios Fair Price

$51.22

18.9% downside

Current Price

$63.18

Undervalued Fair Value Overvalued

According to Bulios Fair Price, DRUG is currently overvalued relative to its market price. How does it work?

Unlock fair price

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Weak
1/9
Valuation
69 /100
Cheap
P/B 2.85x
P/E N/A
EV/EBITDA N/A
Growth
100 /100
Growing
Book val. growth 98.17%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A
Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor
ROIC 12.93%
ROE 12.56%
ROA 7.96%
Debt
69 /100
Low
Debt/Equity 0.00x
Current ratio 121.97x
Int. coverage -3,482.74x
Stability
1 /100
Unstable
Beta 0.09x
EPS volatility 139.33%
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about DRUG
Online

About the company

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in New York, NY.

Sector

Healthcare

Industry

Biotechnology

CEO

Ian McDonald

Employees

26

Headquarters

New York

Upcoming events

22 DEC

Earnings

Upcoming earnings report

100d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.